2型糖尿病论文：2型糖尿病 胰岛素抵抗 祛胰抵方 IL-6 .docVIP

2型糖尿病论文：2型糖尿病 胰岛素抵抗 祛胰抵方 IL-6 【中文摘要】观察祛胰抵方联合二甲双胍对2型糖尿病胰岛素抵抗气阴两虚兼有血瘀痰阻型患者的血清IL-6、胰岛素敏感指数(ISI)、FPG、FINS、2hPG影响的临床研究。方法：将60例2型糖尿病胰岛素抵抗患者随机分为2组,在基础治疗相同的前提下,对照组给予二甲双胍片(山东科源制药有限公司)500mg,每日三次口服；治疗组给予祛胰抵方中药汤剂,每日一剂,水煎两次共取药汁200ml,早晚两次分服,并加以二甲双胍片(山东科源制药有限公司)500mg,每日三次口服。两组均以8周为一疗程。观察两组患者治疗前后血清IL-6、胰岛素敏感指数(ISI)、空腹血糖(FPG)、餐后2小时血糖(2hPG)、空腹胰岛素(FINS)、糖化血红蛋白(HbAlc)、中医临床症状积分、血脂(TC、TG、HDL-C、LDL)的变化。结果：祛胰抵方联合二甲双胍片可以降低IL-6,升高ISI,降低FPG、2hPG、FINS、HbAlc,降低2型糖尿病胰岛素抵抗患者的中医症候积分,能降低患者TG、TC、LDL并升高HDL-C水平,且无明显不良反应及毒副作用,安全性较好。结论：本研究证实,在治疗2型糖尿病患者胰岛素抵抗符合中医气阴两虚兼有血瘀痰滞型方面,祛胰抵方联合西药疗法明显优于单独使用西药疗法,可以明显地降低IL-6并升高ISI,增加胰岛素敏感性；降低FPG、FINS、2hPG、HbA1c;能明显降低患者TG、TC、LDL并升高HDL-C以改善脂代谢紊乱；改善2型糖尿病患者的中医症候积分,改善临床症状；且无明显不良反应及毒副作用,安全性较好,值得临床推广应用。 【英文摘要】Purpose:To observe the therapeutic effect of quyidifang combined with metformin hydrochloride on the serum level of IL-6, insulin sensitivity index (ISI), FPG, FINS,2hPG and other indicators in insulin resistance in type 2 diabetes mullitus.Methods:60 patients with insulin resistance of type 2 diabetes mullitus were randomly divided into two groups, On the premise of same basic, therapy group give metformin hydrochloride (shandong keyuan pharmaceutical Co., LTD.) 500mg, three times daily;The treatment group gives quyidifang Chinese medicine, water frying twice total take a medicine juice 200ml, sooner or later, two times daily, and metformin hydrochloride (shandong keyuan pharmaceutical Co., LTD.) 500mg, three times daily,8 weeks as one period of treatment. Observe both groups of patients before and after the treatment of interleukin-6(IL-6), insulin sensitivity index (ISI), fasting plasma glucose (FPG) and 2-hour plasma glucose (2hPG), fasting insulin (FINS), glycated hemoglobin Alc (HbAlc), Chinese medicine clinical symptom scores, lipid analysis (TC and TG, HDL-c, LDL).Results:the method of quyidifang combined with metformin hydrochloride can obviously reduce IL-6 and elevate ISI, reduce FPG and 2hPG, FINS, HbAlc, improve TCM symptoms, decrease TG, LDL and TC, elevate